Pharmaceutical

Merck's First-Quarter 2024 Financial statements Financial statements Merck Merck published its Q1 2024 financial statements on April 25, 2024.
Novartis's First-Quarter 2024 Financial statements Financial statements Novartis Pfizer published its Q1 2024 financial statements on May 1, 2024.
Roche's First-Quarter 2024 Financial statements Financial statements Roche Roche published its Q1 2024 financial statements on April 24, 2024.
Bristol Myers Squibb's First-Quarter 2024 Financial statements Financial statements Bristol Myers Squibb Bristol Myers Squibb published its Q1 2024 financial statements on April 25, 2024.
AstraZeneca's First-Quarter 2024 Financial statements Financial statements AstraZeneca AstraZeneca published its Q1 2024 financial statements on April 25, 2024.
GSK's First-Quarter 2024 Financial statements GSK Financial statements GSK published its Q1 2024 financial statements on May 1, 2024.
FDA Approves Duvyzat for Duchenne Muscular Dystrophy Treatment FDA Duvyzat, FDA-approved for Duchenne Muscular Dystrophy, targets all genetic variants. A nonsteroidal HDAC inhibitor, offering hope & improved muscle function.
FDA Approves Rezdiffra for NASH Treatment FDA Learn about Rezdiffra's approval for NASH treatment, addressing liver scarring. Discover its efficacy, safety, and implications for patients with noncirrhotic NASH.
Wegovy Approved by FDA for Cardiovascular Risk Reduction FDA Discover how FDA's approval of Wegovy for cardiovascular risk reduction revolutionizes obesity treatment. Learn about its efficacy, warnings, and implications.
FDA Reviews AstraZeneca's Self-Admin Flu Vaccine | FluMist Quadrivalent AstraZeneca FDA Explore AstraZeneca's FDA-reviewed self-admin flu vaccine, FluMist Quadrivalent. Learn about usability studies, regulatory updates, expert views, and the future of flu vaccination.

< Pre 1...83 84 858687 Next >

HOT Topics

Hot Articles